The allegations revolve around payments referring cardiologists received to supervise PET scans from March 2014 to May 2023.

Haemonetics expects the deal to increase its short- and long-term revenue. The all-cash transaction should close by January 2024.

The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure. 

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

The advanced algorithm achieved a sensitivity of 93% and specificity of 98%. It was trained to identify up to five different valvular diseases at the same time from a single audio clip.

Carlyle Group, one of the world’s largest private equity firms, is reportedly working to buy the two business units and turn them into a brand new company. 

Training AI for use in healthcare requires feeding algorithms patient data, and lots of it. This opens data custodians—typically hospitals—to various points of potential legal exposure.

“We carefully made this decision in light of the horrifying recent events," CEO Erez Meltzer said in a statement issued Oct. 10.